Flurbiprofen

Flurbiprofen
Clinical data
Trade namesAnsaid, Ocufen, Strepfen
Other names(±)-2-fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid
AHFS/Drugs.comMonograph
MedlinePlusa687005
Pregnancy
category
  • AU: B2
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding> 99%
MetabolismLiver (CYP2C9)
Elimination half-life4.7-5.7 hours
ExcretionKidney
Identifiers
  • (RS)-2-(2-fluorobiphenyl-4-yl)propanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.023.479 Edit this at Wikidata
Chemical and physical data
FormulaC15H13FO2
Molar mass244.265 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
Melting point117 °C (243 °F)
  • Fc2cc(ccc2c1ccccc1)C(C(=O)O)C
  • InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18) checkY
  • Key:SYTBZMRGLBWNTM-UHFFFAOYSA-N checkY
  (verify)

Flurbiprofen is a member of the phenylalkanoic acid derivative family of nonsteroidal anti-inflammatory drugs (NSAIDs). It is primarily indicated as a pre-operative anti-miotic (in an ophthalmic solution) as well as orally for arthritis or dental pain. Side effects are analogous to those of ibuprofen.[2]

It was derived from propionic acid by the research arm of Boots UK during the 1960s, a period which also included the discovery of ibuprofen, indometacin, diclofenac, naproxen, ketoprofen, and sulindac.[3][4]: 34 

It was patented in 1964 by Boots UK and approved for medical use in 1987.[5] It was approved in the US in 1988; the first generic was approved in 1994.[6]: 158 

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ "Lexicomp: Flurbiprofen". Lexicomp. Wolters Kluwer. Retrieved 25 September 2015.
  3. ^ Rainsford KD (December 2011). "Fifty years since the discovery of ibuprofen". Inflammopharmacology. 19 (6): 293–297. doi:10.1007/s10787-011-0103-7. PMID 22120888.
  4. ^ Fischer J, Ganellin CR (2010). Analogue-based Drug Discovery II. John Wiley & Sons. ISBN 9783527632121.
  5. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 520. ISBN 9783527607495.
  6. ^ Approved Drug Products with Therapeutic Equivalence Evaluations (PDF) (36th ed.). FDA. 2014.